McKenna R M, Schroeder T J
Department of Medicine, University of Manitoba, Winnipeg, Canada.
Clin Biochem. 1991 Feb;24(1):75-80. doi: 10.1016/0009-9120(91)90294-o.
The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on lymphokine production by T lymphocytes. Most efforts to assess immunosuppression in CsA-treated patients have concentrated on measuring some aspect of activated T cell function. These have included monitoring of lymphocyte subsets and the appearance of activated T cell markers, assaying the production of lymphokines and the direct measurement of lymphokines in serum and urine, and most recently measurement of soluble interleukin-2 receptor (SIL2R). Using a new microparticle enzyme immunoassay (MEIA) in a preliminary study of 12 CsA-treated renal transplant recipients, we found significant increases in serum SIL2R levels in patients with rejection and we conclude that MEIA may have some use in the monitoring of CsA-treated patients.
环孢素（CsA）在体内的免疫抑制作用被认为主要涉及其对T淋巴细胞产生淋巴因子的抑制作用。评估接受CsA治疗患者免疫抑制情况的大多数研究都集中在测量活化T细胞功能的某些方面。这些方面包括监测淋巴细胞亚群和活化T细胞标志物的出现、检测淋巴因子的产生以及直接测量血清和尿液中的淋巴因子，最近还包括测量可溶性白细胞介素-2受体（SIL2R）。在一项对12名接受CsA治疗的肾移植受者的初步研究中，我们使用一种新的微粒酶免疫测定法（MEIA），发现发生排斥反应的患者血清SIL2R水平显著升高，我们得出结论，MEIA可能在监测接受CsA治疗的患者方面有一定用途。
